Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Yahoo! Finance
Pacific Time on Monday, January 12, 2026, in San Francisco. Kyle Gano, Chief Executive Officer, will present at the conference. The live presentation will be webcast and can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com . A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month. About Neurocrine Biosciences Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*,
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at JPMorgan Chase & Co. from $179.00 to $177.00. They now have an "overweight" rating on the stock.MarketBeat
- Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Truist Financial Corporation from $172.00 to $169.00. They now have a "buy" rating on the stock.MarketBeat
- Neurocrine Biosciences (NASDAQ:NBIX) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $175.00 price target on the stock, up previously from $173.00.MarketBeat
- Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare ConferencePR Newswire
- Neurocrine Biosciences (NASDAQ:NBIX) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
NBIX
Earnings
- 10/28/25 - Beat
NBIX
Sec Filings
- 1/12/26 - Form 4
- 12/17/25 - Form 4
- 12/15/25 - Form 144
- NBIX's page on the SEC website